Pfizer- Medicines Patent Pool (MPP) Sign Agreement For COVID-19 Oral Candidate
Pfizer has signed an agreement with Medicines Patent Pool (MPP) on November 16, 2021 for Covid-19 Oral Candidate called Paxlovid
Highlights
- Pfizer stated that, it is seeking emergency use authorization from FDA for its investigational COVID-19 pill.
- It will now allow generic drug makers for producing novel antiviral for low-income and middle-income countries.
- Antiviral PF-07321332 is administered with a low-dose ritonavir as Paxlovid.
- The approval will make treatment widely available across 95 low-income and middle-income countries. Thus, 53% of the world’s population will get access to the Oral medicine to treat covid-19.
Background
The agreement and announcement that Pfizer is seeking Emergency Use Authorisation (EUA) for Paxlovid in United States came after Pfizer announced early results from trial. The result showed an 89% reduction in risk of hospitalization or death from COVID-19 among people who got treated in initial three days of symptoms onset.
PF-07321332
It is an antiviral drug, developed by Pfizer. It acts as an orally active 3CL protease inhibitor. The drug is a covalent inhibitor, that binds directly with the catalytic cysteine (Cys145) residue of enzyme. The Pfizer has asked for Emergency use authorisation of PF-07321332/ritonavir combination drugs to treat Covid-19. It will be available under trade name Paxlovid.
How this medicine works?
In the combination, ritonavir slows down the metabolism of PF-07321332 by cytochrome enzymes for maintaining higher circulating concentrations of main drug.
Related Posts
Month: Current Affairs - November, 2021